Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
6 Months : From Apr 2019 to Oct 2019
Respected ‘Silicon Review’ lists Co-Diagnostics in 50 Fastest Growing Companies of 2019
New York City, New York – The Silicon Review’s 50 Fastest Growing Companies of the Year for 2019 features Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests. The July publication includes highlights of Co-Diagnostics’ history, approach to the growing diagnostics (and particularly the polymerase chain reaction, or PCR) sector, and emphasis on quality.
In explaining that the company’s purpose of existence is first and foremost in its motivations, Co-Diagnostics CEO Mr. Dwight Egan also describes the company’s approach to achieving success in part as follows:
“Take what you know you can do, focus on it, and make it work. Anyone can see a need and create a company to address it, but maintaining focus on your key revenue drivers long enough to make meaningful revenue is where so many other companies fall short.”
Release of the interview follows recent news by Co-Diagnostics that their highly specific multiplex test for Zika, dengue, and chikungunya was enthusiastically received at CARPHA 2019, and that domestic sales of their mosquito vector control products have commenced. Analysts from H.C. Wainwright and Maxim Group recently set a price target of $2.00 for CODX.
The Silicon Review is the pre-eminent platform for sharing innovative enterprise solutions developed by established solution providers and upcoming hot enterprises. Emphasizing as a neutral source for decision makers, the publication acts as an excellent medium, allowing top level executives to share their contemporary thoughts and ideas. The feature can be found here: https://bit.ly/2Nv4aC7
About BDA International, Inc.:
BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles may also in some circumstances hold some of shares of client companies in our personal portfolios, including CODX. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release.
The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. Co-Diagnostics is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.
Investor Relations Contact: BDA International www.bda-ir.com